Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
gptkb:public_company |
| gptkbp:CEO |
gptkb:Brian_Goff
|
| gptkbp:focusesOn |
rare diseases
cellular metabolism genetically defined diseases |
| gptkbp:foundedYear |
2007
|
| gptkbp:founder |
gptkb:Craig_Thompson
gptkb:David_Schenkein gptkb:Tak_Mak gptkb:Lewis_Cantley gptkb:Shahriar_Mobashery |
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Agios Pharmaceuticals, Inc.
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableAchievement |
developed first-in-class therapies targeting cellular metabolism
|
| gptkbp:numberOfEmployees |
approximately 350
|
| gptkbp:product |
PYRUKYND (mitapivat)
TIBSOVO (ivosidenib) IDHIFA (enasidenib) |
| gptkbp:soldOncologyBusinessTo |
gptkb:Servier
|
| gptkbp:soldOncologyBusinessYear |
2021
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:AGIO
|
| gptkbp:tradedOn |
gptkb:NASDAQ:_AGIO
|
| gptkbp:website |
https://www.agios.com/
|
| gptkbp:bfsParent |
gptkb:AGIO
|
| gptkbp:bfsLayer |
6
|